RESUMO
Melanoma is a severe metastatic skin cancer with poor prognosis and no effective treatment. Therefore, novel therapeutic approaches using nanotechnology have been proposed to improve therapeutic effectiveness. Lipid-core nanocapsules (LNCs), prepared with poly(ε-caprolactone), capric/caprylic triglyceride, and sorbitan monostearate and stabilized by polysorbate 80, are efficient as drug delivery systems. Here, we investigated the effects of acetyleugenol-loaded LNC (AcE-LNC) on human SK-Mel-28 melanoma cells and its therapeutic efficacies on melanoma induced by B16F10 in C57B6 mice. LNC and AcE-LNC had z-average diameters and zeta potential close to 210 nm and -10.0 mV, respectively. CytoViva(®) microscopy images showed that LNC and AcE-LNC penetrated into SK-Mel-28 cells, and remained in the cytoplasm. AcE-LNC in vitro treatment (18-90×10(9) particles/mL; 1 hour) induced late apoptosis and necrosis; LNC and AcE-LNC (3-18×10(9) particles/mL; 48 hours) treatments reduced cell proliferation and delayed the cell cycle. Elevated levels of nitric oxide were found in supernatant of LNC and AcE-LNC, which were not dependent on nitric oxide synthase expressions. Daily intraperitoneal or oral treatment (days 3-10 after tumor injection) with LNC or AcE-LNC (1×10(12) particles/day), but not with AcE (50 mg/kg/day, same dose as AcE-LNC), reduced the volume of the tumor; nevertheless, intraperitoneal treatment caused toxicity. Oral LNC treatment was more efficient than AcE-LNC treatment. Moreover, oral treatment with nonencapsulated capric/caprylic triglyceride did not inhibit tumor development, implying that nanocapsule supramolecular structure is important to the therapeutic effects. Together, data herein presented highlight the relevance of the supramolecular structure of LNCs to toxicity on SK-Mel-28 cells and to the therapeutic efficacy on melanoma development in mice, conferring novel therapeutic mechanisms to LNC further than a drug delivery system.
Assuntos
Apoptose/efeitos dos fármacos , Adesão Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Lipídeos/química , Melanoma/tratamento farmacológico , Nanocápsulas/administração & dosagem , Animais , Movimento Celular/efeitos dos fármacos , Sistemas de Liberação de Medicamentos , Citometria de Fluxo , Humanos , Masculino , Melanoma/patologia , Camundongos , Camundongos Endogâmicos C57BL , Nanocápsulas/química , Poliésteres/química , Células Tumorais Cultivadas , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
The use of rice bran (RB), soybean (SB) or sunflower seed (SF) oils to prepare lipid-core nanocapsules (LNCs) as controlled drug delivery systems was investigated. LNCs were prepared by interfacial deposition using the preformed polymer method. All formulations showed negative zeta potential and adequate nanotechnological characteristics (particle size 220-230 nm, polydispersity index < 0.20). The environmental safety was evaluated through an in vivo protocol (Allium cepa test) and LNCs containing RB, SB or SF oils did not present genotoxic potential. Clobetasol propionate (CP) was selected as a model drug to evaluate the influence of the type of vegetable oil on the control of the drug release from LNCs. Biphasic drug release profiles were observed for all formulations. After 168 h, the concentration of drug released from the formulation containing SF oil was lower (0.36 mg/mL) than from formulations containing SB (0.40 mg/mL) or RB oil (0.45 mg/mL). Good correlations between the consistency indices for the LNC cores and the burst and sustained drug release rate constants were obtained. Therefore, the type of the vegetal oil was shown as an important factor governing the control of drug release from LNCs.
Assuntos
Anti-Inflamatórios/administração & dosagem , Clobetasol/administração & dosagem , Nanocápsulas/química , Óleos de Plantas/química , Óleo de Soja/química , Preparações de Ação Retardada/química , Preparações de Ação Retardada/toxicidade , Testes de Mutagenicidade , Nanocápsulas/toxicidade , Cebolas/efeitos dos fármacos , Cebolas/genética , Óleos de Plantas/toxicidade , Óleo de Farelo de Arroz , Óleo de Soja/toxicidade , Óleo de GirassolRESUMO
The aim of this work was to investigate if the indomethacin ethyl ester (IndOEt) released from lipid-core nanocapsules (NC) is converted into indomethacin (IndOH) in the intestine lumen, intestine wall or after the particles reach the blood stream. NC-IndOEt had monomodal size distribution (242 nm; PDI 0.2) and zeta potential of -11 mV. The everted rat gut sac model showed IndOEt passage of 0.16 micromol m(-2) through the serosal fluid (30 min). From 15 to 120 min, the IndOEt concentrations in the tissue increased from 6.13 to 27.47 micromol m(-2). No IndOH was formed ex vivo. A fluorescent-NC formulation was used to determine the copolymer bioadhesion (0.012 micromol m(-2)). After NC-IndOEt oral administration to rats, IndOEt and IndOH were detected in the gastrointestinal tract (contents and tissues). In the tissues, the IndOEt concentrations decreased from 459 to 5 microg g(-1) after scrapping, demonstrating the NC mucoadhesion. In plasma (peripheric and portal vein), in spleen and liver, exclusively IndOH was detected. In conclusion, after oral dosing of NC-IndOEt, IndOEt is converted into IndOH in the intestinal lumen and wall before reaching the blood stream. The complexity of a living system was not predicted by the ex vivo gut sac model.
Assuntos
Anti-Inflamatórios não Esteroides/farmacocinética , Portadores de Fármacos/farmacocinética , Indometacina/análogos & derivados , Indometacina/farmacocinética , Mucosa Intestinal/metabolismo , Nanocápsulas/química , Administração Oral , Animais , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/síntese química , Corantes Fluorescentes/farmacocinética , Hidrólise , Indometacina/administração & dosagem , Indometacina/síntese química , Absorção Intestinal , Masculino , Modelos Animais , Nanocápsulas/administração & dosagem , Ratos , Ratos Wistar , Adesivos Teciduais/farmacocinética , Distribuição TecidualRESUMO
We hypothesized that the control of the poly(epsilon-caprolactone) (PCL) nanosphere sizes could be achieved by controlling the size of the primary emulsion droplets considering a combined effect of the ethanol volume fraction in the organic phase and the stirring rate of the primary emulsion. In this way, we prepared poly(epsilon-caprolactone) (PCL) nanospheres in order to evaluate the effect of those variables on the hydrodynamic diameters of the nanoparticles by a 32 factorial design. The size distribution curves considering intensity, volume and number of particles showed monomodal distributions for all formulations. The nanoparticle diameters (z-average) decreased from 423 to 249 nm with the increase in both the ethanol volume fraction from 0.0 to 0.4 and the stirring rate from 9500 to 17500 rpm. The polydispersity indexes ranged from 0.076 to 0.176. A statistical model based on the regression coefficients calculated by the factorial design analysis was proposed in order to predict the nanoparticle diameters. Using the predictive model, the results showed high similarity between the experimental and the predicted nanosphere diameters, validating the model for loaded PCL nanospheres. The backscattering profiles of the primary emulsions prepared using different proportions of ethyl acetate and ethanol showed a reduction in the size of the droplets from 1.659 microm to 0.706 microm with the increase in the ethanol volume fraction and the stirring rate. Ethanol decreased the restoring stress of the droplets as a consequence of the reduction in the interface tension. The decrease in the nanoparticle mean size was a consequence of the droplet size reduction in the primary emulsion.